| ADR Ontology |
| ADR Term |
Blood insulin |
| ADR ID |
BADD_A00565 |
| ADR Hierarchy |
|
| Description |
A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). [MeSH] |
| MedDRA Code |
10005605 |
| MeSH ID |
D007328
|
|
ADR Severity Grade (FAERS)
|
Not Available
|
|
ADR Severity Grade (CTCAE)
|
Not Available
|
| Synonym |
| Blood insulin | Insulin | Plasma insulin | Serum insulin | Immunoreactive insulin | Insulin, Regular | Regular Insulin | Soluble Insulin | Insulin, Soluble | Insulin A Chain | Sodium Insulin | Insulin, Sodium | Novolin | Iletin | Insulin B Chain | Chain, Insulin B |
|
|
| Drugs Leading to the ADR |
| Drug ID | Drug Name | ADR Frequency (FAERS) | ADR Severity Grade (FAERS) | | BADD_D01165 | Insulin lispro | - | - |
| The 1th Page 1
Total 1 Pages
|
|
